EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Cost of Revenue Over TimeContracting
Percentile Rank21
3Y CAGR-37.2%
5Y CAGR-18.7%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

3Y CAGR
-37.2%/yr
vs -18.1%/yr prior
5Y CAGR
-18.7%/yr
Recent deceleration
Acceleration
-19.1pp
Decelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$2.07M-44.3%
2024$3.71M-19.9%
2023$4.63M-44.4%
2022$8.33M+1.8%
2021$8.18M+40.4%
2020$5.82M+116.7%
2019$2.69M-85.5%
2018$18.50M-
2017$0.00-100.0%
2016$815000.00-